Pfizer - "It's more of the same,"

"It's more of the same," said Damien Conover, an analyst with Morningstar. "We're not seeing a dramatic shift that I think Pfizer needs to take."

Reuters

"The message I hear is, 'Don't expect anything radical,' but the challenges require radical change," said Jami Rubin, a drug-industry analyst at Morgan Stanley.

WSJ